The launch of novel drug-eluting balloons to augment the market growth

According to Coherent Market Insights, the global drug-eluting balloon market was valued at USD 420.0 million in 2017, and is projected to exhibit a CAGR of 8.1 percent from 2018 to 2026. The launch of novel drug-eluting balloons by market players is expected to augment the market growth. Key players in the market are focused on launching novel drug-eluting balloons in order to treat coronary artery disease and other diseases and address the critical unmet needs of patients. For instance, in July 2017, Spectranetics Corp. received pre-market approval from US FDA for Stellarex drug-coated balloon that is used for restoration and maintenance of blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease.